Richard Lowenthal

We replace it when it expires or if it's used.

And then the idea is that the nurse then has epinephrine that they can use to treat the child at the school if they have a reaction.

And they're not previously diagnosed and prescribed.

Children that are already diagnosed and prescribed bring their own epinephrine to school.

So this is not necessarily meant for children that have a prescription.

It's really meant for those children that don't have a prescription.

And the other thing I want to mention about it is it's not available in all states yet.

The states are making great progress in updating legislation.

But in order for us to supply NEFI to a school system, the legislation in that state has to provide indemnification for the school personnel to use the epinephrine.

So laws have been put in place some time back to indemnify, protect school personnel.

But most of those laws say injection.

So right now we know, I think more than 20 states have updated their legislation already proactively also encouraged by the school nursing associations because the school nurses really want nephew and they really prefer the nephew rather than injecting the child.

And so the states seem to all be in the process of updating their legislation, but we know that about 20 of them, a little more than 20, I think, have already completed that process.

And we believe that almost all states in the country, probably within the next year, will have their legislation updated to allow the use of NEFE as well.

And then we'll be able to supply NEFE to all schools within the country.

Yeah, well, on our capital, we're fairly well off on our cash at ARS.

We have enough cash capital to get to what we believe a point of cash neutral to where we'll be, I don't want to say profitable because

We may, at the point of getting close to cash neutral, want to spend more on direct-to-consumer or other efforts to promote NEFI and build the market share.

But we believe we have enough cash.

Now, we did recently, in partnership with RA Capital, obtain a $250 million line of credit.